{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:39:59Z","timestamp":1792687199339,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Saga University Project to create Social Impact"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate whether regular prostate-specific antigen (PSA) testing is associated with the receipt of curative treatment for prostate cancer among men in Japan and to identify associated factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted using the claims data from the National Health Insurance and Late-Stage Elderly Health Care System in Saga Prefecture between March 2014 and March 2022. Patients were categorized into PSA testing (\u2265\u20091 test\u2009\u2265\u20096\u00a0months before treatment) and non-PSA testing groups. Curative treatment was defined as either a radical prostatectomy or carbon-ion radiotherapy. Multivariable logistic regression was used to identify the factors associated with curative treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 2,200 patients, 737 (33.5%) underwent PSA testing, and 708 (32.2%) received curative treatment. Patients who underwent PSA testing were older and more likely to participate in Specific Health Checkups. The proportion receiving curative treatment was higher in the PSA testing group (36.4% vs. 30.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Age (OR\u2009=\u20090.85), PSA testing (OR\u2009=\u20091.53), and participation in Specific Health Checkups, which do not include PSA testing, were independently associated with curative treatment (OR\u2009=\u20091.64).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PSA testing was associated with a higher likelihood of receiving curative treatment for prostate cancer. Participation in Specific Health Checkups may reflect a population more engaged in preventive healthcare or with greater access to screening opportunities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-026-02266-3","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:47:51Z","timestamp":1785163671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PSA testing and receipt of curative treatment in elderly Japanese men with prostate cancer: a population-based study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8266-6652","authenticated-orcid":false,"given":"Shohei","family":"Tobu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Isoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"2","key":"2266_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ajur.2016.08.010","volume":"4","author":"K Zhang","year":"2017","unstructured":"Zhang K, Bangma CH, Roobol MJ. Prostate cancer screening in Europe and Asia. Asian J Urol. 2017;4(2):86\u201395.","journal-title":"Asian J Urol"},{"issue":"6","key":"2266_CR2","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1158\/1055-9965.EPI-19-1228","volume":"29","author":"E Saito","year":"1993","unstructured":"Saito E, Hori M, Matsuda T, Yoneoka D, Ito Y, Katanoda K. Long-term trends in prostate cancer incidence by stage at diagnosis in Japan using the multiple imputation approach, 1993\u20132014. Cancer Epidemiol Biomarkers Prev. 1993;29(6):1222\u20138.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2266_CR3","unstructured":"National Cancer Center Japan. Cancer Statistics in Japan. Prostate cancer: incidence and mortality. 2023. Available from: https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/cancer\/20_prostate.html."},{"issue":"13","key":"2266_CR4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schr\u00f6der","year":"2009","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"2266_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.7326\/0003-4819-149-3-200808050-00008","volume":"149","author":"U.S. Preventive Services Task Force","year":"2008","unstructured":"U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(3):185\u201391.","journal-title":"Ann Intern Med"},{"key":"2266_CR6","unstructured":"Denmeade SR, Isaacs JT. The role of prostate-specific antigen in the clinical evaluation of prostatic disease. In: Parekh DJ, editor. Prostate Cancer Screening. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470216\/."},{"issue":"1","key":"2266_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00262-2","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer Nat Rev Dis Primers. 2021;7(1):9. https:\/\/doi.org\/10.1038\/s41572-020-00262-2.","journal-title":"Prostate cancer Nat Rev Dis Primers"},{"issue":"2","key":"2266_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63\u201389.","journal-title":"World J Oncol"},{"issue":"13","key":"2266_CR9","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","volume":"360","author":"GL Andriole","year":"2009","unstructured":"Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310\u20139.","journal-title":"N Engl J Med"},{"issue":"11","key":"2266_CR10","doi-asserted-by":"publisher","first-page":"1080800","DOI":"10.3389\/fpubh.2023.1080800","volume":"4","author":"Y Wang","year":"2023","unstructured":"Wang Y, Xiao M, Zhang Y, Hong Z, Zhang R, Xu Q, et al. Investigation of awareness rate of prostate-specific antigen (PSA) among the general public in China and analysis of influencing factors. Front Public Health. 2023;4(11):1080800.","journal-title":"Front Public Health"},{"issue":"12","key":"2266_CR11","doi-asserted-by":"publisher","first-page":"e011932","DOI":"10.1136\/bmjopen-2016-011932","volume":"6","author":"K Pickles","year":"2016","unstructured":"Pickles K, Carter SM, Rychetnik L, Entwistle VA. Doctors\u2019 perspectives on PSA testing illuminate established differences in prostate cancer screening rates between Australia and the UK: a qualitative study. BMJ Open. 2016;6(12):e011932.","journal-title":"BMJ Open"},{"issue":"5","key":"2266_CR12","doi-asserted-by":"publisher","first-page":"e0303203","DOI":"10.1371\/journal.pone.0303203","volume":"19","author":"LA Parker","year":"2024","unstructured":"Parker LA, Caballero-Romeu JP, Chilet-Rosell E, Hernandez-Aguado I, G\u00f3mez-P\u00e9rez L, Alonso-Coello P, et al. Knowledge and practices regarding prostate cancer screening in Spanish men: the importance of personal and clinical characteristics (PROSHADE study). PLoS ONE. 2024;19(5):e0303203.","journal-title":"PLoS ONE"},{"key":"2266_CR13","doi-asserted-by":"publisher","first-page":"9275466","DOI":"10.1155\/2022\/9275466","volume":"2022","author":"Y An","year":"2022","unstructured":"An Y, Sun JX, Xu MY, Liu CQ, Xu JZ, Zhong XY, et al. Statin use is associated with better prognosis of patients with prostate cancer after definite therapies: A systematic review and meta-analysis of cohort studies. J Oncol. 2022;2022:9275466.","journal-title":"J Oncol"},{"issue":"4","key":"2266_CR14","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41391-021-00351-2","volume":"24","author":"AI Peltomaa","year":"2021","unstructured":"Peltomaa AI, Raittinen P, Talala K, Taari K, Tammela TLJ, Auvinen A, et al. Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users: a population-based cohort study. Prostate Cancer Prostatic Dis. 2021;24(4):917\u201324.","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02266-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02266-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02266-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:03:06Z","timestamp":1792684986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02266-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2266"],"URL":"https:\/\/doi.org\/10.1186\/s12894-026-02266-3","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"26 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Saga University Faculty of Medicine (Approval No. 2024-08-R-02). The requirement for informed consent was waived due to the retrospective nature of the study and the use of anonymized data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"254"}}